Sanofi: Dengue trials

The registry lists 36 Dengue studies with Sanofi as lead sponsor. 1 are open to participants now and 24 have results posted.

Phase 2 17Phase 3 9No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Dengvaxia US Pregnancy RegistryRecruitingNCT04486638
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®CompletedNCT02993757Phase 3Results posted
• Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy SubjectsTerminatedNCT02992418Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®CompletedNCT02979535Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose ScheduleCompletedNCT02824198Phase 2Results posted
• Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive AdultsCompletedNCT02741128Phase 2Results posted
• Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of AgeCompletedNCT02628444Phase 2Results posted
• Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose ScheduleCompletedNCT02623725Phase 2Results posted
• Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy StudyCompletedNCT01983553Results posted
• Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue VaccineCompletedNCT01943825Phase 2Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in IndiaCompletedNCT01550289Phase 2Results posted
• Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever VaccineCompletedNCT01488890Phase 2Results posted
• Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy ToddlersCompletedNCT01436396Phase 3Results posted
• Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy ToddlersCompletedNCT01411241Phase 3Results posted
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin AmericaCompletedNCT01374516Phase 3Results posted
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in AsiaCompletedNCT01373281Phase 3Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in MalaysiaCompletedNCT01254422Phase 3Results posted
• Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South AmericaCompletedNCT01187433Phase 2Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Adults in AustraliaCompletedNCT01134263Phase 3Results posted
• Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin AmericaCompletedNCT00993447Phase 2Results posted
• Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in SingaporeCompletedNCT00880893Phase 2Results posted
• Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy SubjectsCompletedNCT00875524Phase 2Results posted
• Efficacy and Safety of Dengue Vaccine in Healthy ChildrenCompletedNCT00842530Phase 2Results posted
• Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 YearsCompletedNCT00788151Phase 2Results posted
• Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the USCompletedNCT00617344Phase 2Results posted
• Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information UpdateCompletedNCT04170140
• Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in ColombiaActive, not recruitingNCT04113330
• Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During PregnancyCompletedNCT04023708
• Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue VaccineCompletedNCT02948933
• Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue VaccineCompletedNCT02827162
• Prospective Dengue Seroprevalence Study in 5 to 10 Year-old ChildrenCompletedNCT01477671
• Study of Febrile Illness for Dengue-Endemic Areas in Latin AmericaCompletedNCT01293331
• Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in AsiaCompletedNCT01218906
• A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the PhilippinesCompletedNCT01064141Phase 2
• Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve AdultsCompletedNCT00740155Phase 2
• Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult SubjectsCompletedNCT00730288Phase 2